论文部分内容阅读
目的探讨磷脂爬行酶1(PLSCR1)在肝细胞癌中的表达及临床意义。方法采用免疫组化检测44例肝细胞癌组织、癌旁组织及10例正常肝组织中PLSCR1的表达,分析其与肝细胞癌临床病理特征的关系。结果肝细胞癌组织中PLSCR1阳性表达高于癌旁组织和正常肝组织(P<0.01),癌旁组织与正常肝组织比较差异无统计学意义(P>0.05)。PLSCR1的表达与肝细胞癌患者HBsAg和TNM分期密切相关(P<0.05),与患者性别、年龄、肿瘤大小、甲胎蛋白、分化程度及淋巴结转移无明显相关(P>0.05)。结论 PLSCR1在肝细胞癌组织中高表达,可能与肝细胞癌的发生、发展有关。
Objective To investigate the expression of phospholipid repressing enzyme 1 (PLSCR1) in hepatocellular carcinoma (HCC) and its clinical significance. Methods Immunohistochemistry was used to detect the expression of PLSCR1 in 44 hepatocellular carcinoma tissues, adjacent noncancerous tissues and 10 normal liver tissues. The relationship between the expression of PLSCR1 and the clinicopathological features of hepatocellular carcinoma was analyzed. Results The positive expression of PLSCR1 in hepatocellular carcinoma was significantly higher than that in paracancerous tissues and normal liver tissues (P <0.01). There was no significant difference between adjacent tissues and normal liver tissues (P> 0.05). The expression of PLSCR1 was closely related to the stage of HBsAg and TNM in patients with hepatocellular carcinoma (P <0.05). There was no significant correlation between the expression of PLSCR1 and gender, age, tumor size, alpha fetoprotein, differentiation and lymph node metastasis (P> 0.05). Conclusion The high expression of PLSCR1 in hepatocellular carcinoma may be related to the occurrence and development of hepatocellular carcinoma.